Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC

Autor:	Robert N. Raju, R. Leonard, Casey Cunningham, S. Packer, Ravi Salgia, Donald A. Richards, J. Arseneau, L. Gregoire, M. J. Uprichard, E. Haltom
Rok vydání:	2005
Předmět:	Cancer Research Pathology medicine.medical_specialty business.industry medicine.medical_treatment Stage iiib Cytokine Oncology Docetaxel Fibroblast activation protein alpha Stroma Cancer research Talabostat Medicine In patient business medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:7120-7120
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.7120
Popis:	7120 Background: Talabostat (T) is an oral inhibitor of dipeptidyl peptidases such as fibroblast activation protein found on the stroma of tumors. Administration of T stimulates cytokine and chemok...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b8d57335c94b3c63652e63936ab93f3f https://doi.org/10.1200/jco.2005.23.16_suppl.7120 Zobrazit plný text záznamu